What is the recommended next therapeutic step for a 60-year-old patient with chronic post‑chikungunya polyarthritis involving metacarpophalangeal joints, cervical spine, burning pain in the soles and palms, headache, and a history of eosinophilic allergic disease, who is currently on hydroxychloroquine and methotrexate with normal C‑reactive protein, erythrocyte sedimentation rate, and rheumatoid factor?

Escalate to a Biologic DMARD (TNF Inhibitor or Alternative)

For this patient with chronic post-chikungunya polyarthritis failing hydroxychloroquine and methotrexate, the next therapeutic step is to add a biologic DMARD—specifically a TNF inhibitor, abatacept, or tocilizumab—while continuing methotrexate. 1

Clinical Context and Rationale

This patient presents with persistent inflammatory arthritis one year after chikungunya infection, manifesting as:

• Metacarpophalangeal joint involvement with swelling
• Cervical spine involvement
• Burning pain in palms and soles (likely inflammatory neuropathic component)
• Failure of conventional synthetic DMARDs (HCQ + MTX)
• Normal inflammatory markers (CRP, ESR, RF)

The normal inflammatory markers do not exclude active inflammatory disease—post-chikungunya arthritis frequently presents with seronegative, sometimes low-inflammatory-marker disease that nonetheless causes significant joint destruction and disability 2, 3, 4.

Treatment Algorithm

Step 1: Verify Adequate DMARD Optimization

Before escalating, confirm:

• Methotrexate dose: Should be 20-25 mg/week (or maximum tolerated dose) 5, 1
• Route: Consider switching to subcutaneous methotrexate if oral absorption is questionable 5
• Duration: MTX requires 4-6 months for maximum effect 1

If MTX has been optimized for adequate duration without response, proceed to biologic therapy.

Step 2: Add Biologic DMARD

Based on EULAR recommendations for inflammatory arthritis with inadequate response to conventional synthetic DMARDs 1, 6:

First-line biologic options (in combination with MTX):

1. TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab) 1, 6
2. Abatacept (T-cell costimulation blockade) 5, 1
3. Tocilizumab (IL-6 receptor blockade) 5, 1

All three classes have Level 1a evidence and Grade A recommendations for inflammatory arthritis failing conventional DMARDs 1. The choice depends on:

• Patient comorbidities (eosinophilic allergic history may favor avoiding TNF inhibitors if recurrent infections are a concern)
• Access and cost considerations
• Patient preference

Step 3: Short-term Glucocorticoid Bridge

While initiating biologic therapy, add:

• Low-dose prednisone (≤10 mg/day) or equivalent for symptom control 1, 6
• Taper and discontinue within 3-6 months as biologic takes effect 7, 1
• Intra-articular glucocorticoid injections for individual problematic joints (e.g., MCPs, cervical facets if accessible) 7, 1

Avoid prolonged glucocorticoid use given cumulative toxicity 7, 8.

Post-Chikungunya Arthritis-Specific Evidence

Post-chikungunya chronic arthritis often mimics rheumatoid arthritis and responds to similar treatment strategies 2, 3, 4:

• Methotrexate monotherapy (up to 25 mg/week) shows good response in many cases 3, 9
• TNF inhibitors have demonstrated good tolerance and efficacy in post-chikungunya arthritis refractory to MTX 3
• Combination therapy (MTX + biologic) is more effective than monotherapy for persistent inflammatory arthritis 3, 4

One study of 147 post-chikungunya patients found that 13 required anti-TNF therapy with good tolerance and expected efficacy 3. Another cohort showed that 4-week treatment with MTX and leflunomide (with short-term dexamethasone) produced sustained improvement 9, though your patient has already failed MTX.

Alternative Consideration: Triple Conventional DMARD Therapy

If biologic access is limited, consider triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) 5, 1:

• This is appropriate for patients without poor prognostic factors
• However, your patient has already failed MTX + HCQ, and adding sulfasalazine alone is unlikely to provide adequate benefit
• Biologics are preferred given treatment failure and disease severity 1

Monitoring and Reassessment

• Assess response at 3 months, with target of low disease activity or remission by 6 months 1, 6
• Use composite disease activity measures (DAS28, CDAI, or SDAI) 1
• If inadequate response to first biologic after 3-6 months, switch to alternative biologic with different mechanism of action 1, 6:
  • If TNF inhibitor fails → switch to abatacept, tocilizumab, or rituximab
  • If abatacept fails → switch to TNF inhibitor or tocilizumab
  • Up to one switch within the same class (e.g., TNF to TNF) is reasonable 1

Critical Pitfalls to Avoid

1. Do not assume normal inflammatory markers mean inactive disease—post-chikungunya arthritis can be destructive despite normal CRP/ESR 2, 4
2. Do not delay biologic therapy in patients with persistent symptoms after adequate DMARD trial—early aggressive treatment prevents joint destruction 7, 1
3. Do not use prolonged high-dose glucocorticoids as maintenance therapy—cumulative toxicity outweighs benefits 7, 8
4. Do not stop methotrexate when adding biologic—combination therapy is superior 1, 6
5. Screen for latent tuberculosis and hepatitis B before initiating biologic therapy 1

Addressing the Burning Sensation

The burning pain in palms and soles may represent:

• Inflammatory neuropathic pain from chikungunya (common manifestation) 2
• Small fiber neuropathy secondary to chronic inflammation
• Enthesitis (consider ultrasound evaluation)

This symptom often improves with control of underlying inflammation via biologic therapy 3. If it persists despite disease control, consider adjunctive neuropathic pain medications (gabapentin, pregabalin, duloxetine).